PROK
ProKidney
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
PROK Profile
Prokidney Corp.
A US-based biotech company that develops and commercializes novel therapies for chronic kidney disease
Biological Technology
02/25/2021
06/30/2021
NASDAQ Stock Exchange
204
12-31
Common stock
2000 Frontis Plaza Blvd., Suite 250, Winston-Salem, NC 27103
--
ProKidney Corp. is a new company incorporated under the laws of the Cayman Islands on February 25, 2021. The company is a pioneer in the innovative treatment of chronic kidney disease (CKD) through cell therapy. The company's lead product candidate, REACT (Renal Autologous Cell Therapy), is a first-of-its-kind patented disease-modifying autologous cell therapy that not only has the potential to slow and stabilize the progression of CKD, but also drives significant improvements in renal function in some cases.